All News
SGLT2 Inhibitors Reduce Gout Flares and CV Events
A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring emergency department (ED) visits or hospitalizations.
Read Article
Dr. Joseph Flood (1952-2023) - Past ACR President
Dr Joseph Flood, a past president of the American College of Rheumatology, passed away on July 13, 2023 at age 70 due to complications of liver disease, diabetes and liver cancer.
Read Article
MMWR: Arthritis Among Children and Adolescents
The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021.
https://t.co/pQnB3zV7sw https://t.co/nrLZ8Uazgh
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM: 19 yoM w/ 3yr hx of Raynauds, periungual erythema. Nailfold capillaroscopy showed giant nailfold capillaries, branched & bushy neovascularized capillary loops & reduced capillary density; suggesting clinically amyopathic dermatomyositis https://t.co/Wvnp7wCajx
Links:
Dr. John Cush RheumNow ( View Tweet)
Double blind RCT of 101 active AS patients with BASDAI ≥4 showed the IL-23 inhibitor, tildrakizumab was not superior to placebo after 24 weeks (ASAS20: 74% on tildrakizumab 200 mg vs 80% on PBO). Study was terminated after wk 24 interim analysis https://t.co/zZxiAk6A5o https://t.co/P1tNX8BN6C
Links:
Dr. John Cush RheumNow ( View Tweet)
EMA's CHMP adopted a positive opinion for 1st tocilizumab biosimilar, Tyenne® (from Fresenius Kab), for Rx of RA, systemic JIA, poly JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome. No decision yet on IL6 biosimilar in USA https://t.co/w00yGfm3Vv https://t.co/UzxPvBf1nG
Links:
Dr. John Cush RheumNow ( View Tweet)
RNase Treatment of Autoimmune Disorders
U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders.
https://t.co/JhOk4rEdoG https://t.co/E8UxJ94ShN
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofactitinib in PsA & RA: Nine Year Safety Data
A real-world, post-marketing surveillance (PMS) of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified.
https://t.co/nVglUz6FJC https://t.co/t3dI5SzjJa
Links:
Dr. John Cush RheumNow ( View Tweet)
Horizon announced its phase II RCT of Daxdilimab (anti-ILT7 mAB targeting dendritic cells) failed to meet its primary endpoint - BICLA response w/ pred ≤7.5 mg/day @wk48 (DAX=PBO). DAX also under study in alopecia areata, DLE, lupus nephritis https://t.co/4EH6rBS0sJ https://t.co/B1uceAPGTB
Links:
Dr. John Cush RheumNow ( View Tweet)
Voclosporin in SLE - Long-Term Safety and Efficacy
The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.
https://t.co/uiqi8J9rrP https://t.co/3r6aAI3WTj
Links:
Dr. John Cush RheumNow ( View Tweet)
"Ask Cush Anything" Returns
Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything”
https://t.co/bjMuMPlCHK https://t.co/rmAwOsNSvq
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 48 Jo-1+ anti synthetase pts shows Ab levels signif correlated w/ activity (r=0.4, p=.03) & CK (r=0.34, p=.002) & were signif higher w/ active disease (91.7 vs 44.4 IU/L). https://t.co/5TJYatLsEk Modest correl. prev seen https://t.co/tIsLCODKB6 https://t.co/rWA6M50ufV
Dr. John Cush RheumNow ( View Tweet)
Infectious Risk with B Cell Therapies in Lupus
A UK registry study of moderate to severe SLE showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.
https://t.co/Dko5UQAl0G https://t.co/DQcrWtzQuY
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA has a review of "Diagnosis and Treatment of Hip and Knee Osteoarthritis".
Affecting 240 million people worldwide, >32 million in the US. OA Risk factors include age, female, obesity, genetics, & trauma/injury. OA pts have more comorbidities https://t.co/fGgTLWj8Hc https://t.co/65hpkI8oo0
Links:
Dr. John Cush RheumNow ( View Tweet)
Danger with Hydroxychloroquine Nonadherence in SLE
A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.
https://t.co/1trDJoTypb https://t.co/c7oPyxF8mC
Links:
Dr. John Cush RheumNow ( View Tweet)
Don't bother just to be better than your contemporaries or predecessors. Try to be better than yourself. - William Faulkner (1897 - 1962)
Dr. John Cush RheumNow ( View Tweet)
SLE and Pregnancy Outcomes
Obstetric complications and poor pregnancy outcomes are not uncommon in women with systemic lupus erythematosus (SLE), especially with active disease.
https://t.co/ojFccY6kTT https://t.co/kJpIZP1kSd
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis
The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest.
https://t.co/OxcpnJ5EOe https://t.co/ggOnwt3wck
Links:
Dr. John Cush RheumNow ( View Tweet)
Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/hkDuCOYICy https://t.co/ZGicUqXN8l
Links:
Dr. John Cush RheumNow ( View Tweet)
Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/H90D9LzNSo https://t.co/JiS6HL38Jg
Links:
Dr. John Cush RheumNow ( View Tweet)
